21 March 2017Big Pharma

Video interview: Taylor Wessing on SPCs at the CJEU

There have been two significant references on issues that have been "left hanging" by the Court of Justice of the European Union (CJEU) in the last spate of decisions, says Paul England, senior associate at Taylor Wessing, in a video interview with LSIPR.  England discusses the two important references to the CJEU with regard to supplementary protection certificates.  Here he covers the Teva v Gilead Sciences and Abraxis Bioscience references, and talks about the importance of these cases.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
19 March 2026   The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.
Big Pharma
16 March 2026   Research from the International Trademark Association finds in-house counsel taking on more strategic work while facing shrinking budgets, prompting a shift towards alternative billing and greater use of AI.
Big Pharma
10 March 2026   UK government funding will support the London-based IP crime unit until 2029, as EUIPO and European authorities step up efforts to tackle unsafe counterfeits.